ES550831A0 - Procedimiento para la preparacion de nuevos antigenos nativos pseudomonas-flagella (h) - Google Patents

Procedimiento para la preparacion de nuevos antigenos nativos pseudomonas-flagella (h)

Info

Publication number
ES550831A0
ES550831A0 ES550831A ES550831A ES550831A0 ES 550831 A0 ES550831 A0 ES 550831A0 ES 550831 A ES550831 A ES 550831A ES 550831 A ES550831 A ES 550831A ES 550831 A0 ES550831 A0 ES 550831A0
Authority
ES
Spain
Prior art keywords
flagellar
antigens
pct
pseudomonas
certain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES550831A
Other languages
English (en)
Other versions
ES8800275A1 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oesterreichisches Institut fuer Haemoderivate
Original Assignee
Immuno AG
Immuno AG fuer Chemisch Medizinische Produkte
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immuno AG, Immuno AG fuer Chemisch Medizinische Produkte filed Critical Immuno AG
Publication of ES8800275A1 publication Critical patent/ES8800275A1/es
Publication of ES550831A0 publication Critical patent/ES550831A0/es
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/104—Pseudomonadales, e.g. Pseudomonas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/825—Bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ES550831A 1985-01-14 1986-01-13 Procedimiento para la preparacion de nuevos antigenos nativos pseudomonas-flagella (h) Expired ES8800275A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AT0007285A AT384032B (de) 1985-01-14 1985-01-14 Verfahren zur herstellung von polydispersen nativen pseudomonas-flagella(h)-antigenen (fag)

Publications (2)

Publication Number Publication Date
ES8800275A1 ES8800275A1 (es) 1987-11-01
ES550831A0 true ES550831A0 (es) 1987-11-01

Family

ID=3480790

Family Applications (1)

Application Number Title Priority Date Filing Date
ES550831A Expired ES8800275A1 (es) 1985-01-14 1986-01-13 Procedimiento para la preparacion de nuevos antigenos nativos pseudomonas-flagella (h)

Country Status (10)

Country Link
US (1) US4831121A (es)
EP (1) EP0208743B1 (es)
JP (1) JPH085801B2 (es)
AT (2) AT384032B (es)
CA (1) CA1263307C (es)
DE (1) DE3686961D1 (es)
DK (1) DK172329B1 (es)
ES (1) ES8800275A1 (es)
FI (1) FI85221C (es)
WO (1) WO1986003974A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5237053A (en) * 1986-06-24 1993-08-17 Immuno Aktiengesellschaft Preparation active against Pseudomonas aeruginosa infections and methods of producing them
AT391080B (de) * 1986-06-24 1990-08-10 Immuno Ag Verfahren zur herstellung von gegen pseudomonas aeruginosa infektionen wirksamen praeparationen
AT390192B (de) * 1988-08-29 1990-03-26 Immuno Ag Gegen pseudomonas aeruginosa-infektionen wirksame praeparationen sowie immunglobuling-h|ltige, gegen bakterium pseudomonas aeruginosa wirksame praeparationen
US4994161A (en) * 1989-02-02 1991-02-19 University Of New Hampshire Apparatus and method for macromolecular charge determination
CA2560923A1 (en) * 2004-03-26 2005-10-06 Quark Biotech, Inc. Annexin ii and uses thereof
WO2009033009A2 (en) * 2007-09-05 2009-03-12 Inotek Pharmaceuticals Corporation Antibodies against flagellin and uses thereof
US20100239583A1 (en) * 2009-03-04 2010-09-23 Inotek Pharmaceuticals Corporation Antibodies against flagellin and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3928565A (en) * 1971-10-19 1975-12-23 Yuzuru Homma Pharmaceutical preparation of pseudomonas aeruginosa bacterial component possessing anti-tumor and anti-infection properties
JPS51133489A (en) * 1975-05-14 1976-11-19 Tokyo Daigaku Process for producing microbial components of pseudomonas aeruginosa h aving antimicrobial and antitumor activities
FR2460139A1 (fr) * 1979-06-29 1981-01-23 Pasteur Institut Fraction antigenique glycopeptidique vaccinante a tres grande immunogenicite isolee de cultures de germes pathogenes, procedes d'isolement de cette fraction et vaccins contenant ladite fraction
US4271147A (en) * 1980-01-10 1981-06-02 Behringwerke Aktiengesellschaft Process for the isolation of membrane proteins from Neisseria meningitidis and vaccines containing same
EP0048422A3 (en) * 1980-09-15 1983-08-24 Bactex Incorporated Pili of pseudomonas aeruginosa and utilization of same as vaccines against infectionary p.aeruginosa
US4470924A (en) * 1981-12-30 1984-09-11 Iglewski Barbara M Nontoxic, immunologically crossreactive toxin A protein from Pseudomonas aeruginosa
US4578458A (en) * 1983-03-23 1986-03-25 Brigham And Women's Hospital Mucoid exopolysaccharide vaccine against Pseudomonas aeruginosa

Also Published As

Publication number Publication date
CA1263307A (en) 1989-11-28
JPH085801B2 (ja) 1996-01-24
WO1986003974A1 (en) 1986-07-17
EP0208743A1 (de) 1987-01-21
ES8800275A1 (es) 1987-11-01
DE3686961D1 (de) 1992-11-19
AT384032B (de) 1987-09-25
DK421486D0 (da) 1986-09-03
EP0208743B1 (de) 1992-10-14
JPS62501363A (ja) 1987-06-04
DK421486A (da) 1986-09-03
ATE81471T1 (de) 1992-10-15
ATA7285A (de) 1987-02-15
FI85221C (fi) 1992-03-25
FI85221B (fi) 1991-12-13
FI863677A (fi) 1986-09-11
CA1263307C (en) 1989-11-28
DK172329B1 (da) 1998-03-23
FI863677A0 (fi) 1986-09-11
US4831121A (en) 1989-05-16

Similar Documents

Publication Publication Date Title
Elsayed et al. Isolation of purified allergens (cod) by isoelectric focusing
ES2071706T3 (es) Metodo para fraccionar proteinas plasmaticas.
BR9107206A (pt) Processo para produzir uma variante de proteina que evoca uma resposta imunogenica diminuida em animais,produtos obtidos,composicao e uso
DK371087D0 (da) Mamalialt interleukin-4
AR017866A1 (es) Metodo para incrementar las inmunorespuestas de vacunas de acidos nucleicos, composiciones farmaceuticas de aplicacion en dicho metodo, procedimientopara preparar dichas composiciones y vacunas utilizadas en dicho metodo.
ES8103976A1 (es) Un metodo de producir proteinas de interferon humano de for-ma le
DE69032806D1 (de) Verfahren zur isolierung und reinigung von rezeptoren für transferrin und lactoferrin von bakterien und herstellung von impfstoffen, die sie enthalten
ATE113654T1 (de) Follistatin und verfahren zur reinigung desselben.
DK614987D0 (da) Syntetiske htlv-iii peptider, praeparater og anvendelser deraf
DK0506748T3 (da) Aminosyrer, peptider eller derivater deraf bundet til fedtstoffer
ES550831A0 (es) Procedimiento para la preparacion de nuevos antigenos nativos pseudomonas-flagella (h)
PRIMOR et al. Pardaxin: the toxic factor from the skin secretion of the flatfish Pardachirus marmoratus (Soleidae)
ES2080047T3 (es) Peptidos hiv y metodos para la deteccion de hiv.
DE3585713D1 (de) Immunoverstaerker und verfahren zu ihrer herstellung.
Hatahara et al. Isolation and characterization of a fibrogenic factor from CCl4-damaged rat liver
Postlethwaite et al. Latent lymphokines: isolation of guinea pig latent lymphocyte-derived chemotactic factor for monocytes. Its activation by trypsin and a soluble factor from macrophages
TAYLOR et al. Markedly enhanced production of gamma interferon in murine T lymphocytes treated with lentil lectin and the diterpene ester, mezerein
DK412389D0 (da) Fremgangsmaade til udvinding af oprenset epi protein fra en fermenteringsoploesning
KR910005887A (ko) 면역원성 물질의 고-보존된 아미노산 서열에 대한 항체, 이의 항체의 제조 방법 및 면역 감정에서의 이의 용도
ATE9906T1 (de) Verfahren zum herstellen und erhalten von anaphylatoxin und cocytotaxin enthaltenden leukotaxin-praeparaten und von anaphylatoxinund cocytotaxin-proteinen in einer molekular homogenen und biologisch aktiven form.
MAENO et al. Characterization of mineral-binding 40-kDa glycoprotein extracted from young adult rabbit alveolar bone
PT85248A (fr) Procede d:isolement d:un peptide presentant des proprietes antigeniques isole de la proteine 28kd de ?s.mansoni?,anticorps monoclonaux reconnaissant au moins un epitope dudit peptide et applications de celui-ci dans l:induction de la synthese d:anticorps neutralisants
JPS5767592A (en) Protein having reassociating properties and its preparation